Oncology Peer Review On-The-Go: 1-on-1 With Richard L. Schilsky, MD, on Molecular Profiling in GI Cancers

Podcast

Schilsky joined CancerNetwork®’s podcast to discuss ASCO’s Advance of the Year, the top priorities moving forward, and the COVID-19 pandemic.

This week, CancerNetwork® sat down for a one-on-one conversation with former Chief Medical Officer and Executive Vice President of the American Society for Clinical Oncology, Richard L. Schilsky, MD, to discuss ASCO’s 2021 “Advance of the Year,” molecular profiling in gastrointestinal cancers.

Schilsky discussed the progress being made in this field and the top research contributing to the momentum in gastrointestinal cancers, while also elaborating on health equity in cancer research, ASCO’s top research priorities moving forward, and more.

He also explained the changes forced on clinical trials due to the COVID-19 pandemic, and how he anticipates trials can leverage these adjustments moving forward in a post-COVID world.

Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.

Related Videos
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Rahul Gosain, MD; Sam Klempner, MD; and Rohit Gosain, MD, presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.
Patients with unresectable or metastatic esophageal squamous cell carcinoma and higher PD-L1 expression may benefit from treatment with tislelizumab, according to Syma Iqbal, MD.
Quantifying disease volume to help identify potential recurrence following surgery may be a helpful advance, according to Sean Dineen, MD.